• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » ICU Medical to pay Pfizer $1B for Hospira infusion pump biz

ICU Medical to pay Pfizer $1B for Hospira infusion pump biz

October 6, 2016 By Brad Perriello

ICU Medical acquires Hospira infusion from PfizerICU Medical (NSDQ:ICUI) agreed to pay $1 billion in cash and stock for the Hospira infusion pump business owned by Pfizer (NYSE:PFE), confirming rumors that swirled earlier this year that the drug giant was looking to sell the business.

The deal calls for ICU Medical to put up $400 million worth of new shares and $600 million in cash, leaving Pfizer with a 16.6% stake in ICU. The acquisition, expected to close during the 1st quarter of 2017, includes IV pumps, solutions and devices made by the Hospira Infusion Systems business. ICU pegged its pro-forma annual revenues after the deal at roughly $1.45 billion, based on trailing 12-month results as of June.

“The combination of these 2 businesses is the natural evolution of a productive relationship that began more than 20 years ago when Hospira began integrating ICU Medical’s needle-free technology into their infusion offering globally,” ICU Medical CEO Vivek Jain said in prepared remarks. “By acquiring the Hospira Infusion Systems business, currently our largest single customer, we create a pure-play infusion business with the focus and scale to compete globally, eliminate our single customer concentration issue, and have a significant value creation opportunity as a much larger company. We look forward to serving more customers as we continue to bring clinical and economic value to the marketplace.”

“We are pleased that Hospira Infusion Systems is combining with ICU Medical, and we believe the combined company will be well positioned in the marketplace to deliver value to customers through its strong product portfolio and the expertise of colleagues from both companies. I’m proud of the Hospira Infusion Systems team and their positive impact on patients around the world,” added Pfizer Essential Health president John Young.

Pfizer can nominate a board member for ICU Medical as long as it still holds at least a 10% stake in the company. The deal also includes provisions limiting Pfizer’s ability to trade ICUI shares for 18 months after the transaction closes, the companies said.

ICU Medical updated its 2016 guidance, saying it now expects to post numbers “slightly above” the top end of its prior outlook for adjusted earnings per share of $4.60 on sales of $370 million. Third-quarter adjusted EPS are forecast at $1.20 on sales of $96 million, the company said.

ICUI shares rose about 7% to $135 apiece in light pre-market trading today.

Barclays and Wells Fargo Securities advised ICU Medical on the deal, with Latham & Watkins as legal advisor. Pfizer tapped Goldman, Sachs & Co. and Guggenheim Securities as advisors, with Skadden, Arps, Slate, Meagher & Flom and Ropes & Gray as legal advisors.

Pfizer paid $15 billion for Hospira in September 2015, its largest-ever buyout. In addition to the infusion pump business, Hospira makes generic versions of injectable drugs and biosimilars including a knockoff of Johnson & Johnson‘s (NYSE:JNJ) blockbuster anti-inflammatory Remicade. Pfizer paid $90 per share in cash, a 39% premium to Hospira’s closing stock price the day before the February bid.

Filed Under: Drug Pumps, Mergers & Acquisitions, Wall Street Beat Tagged With: Hospira Inc., ICU Medical Inc., Pfizer

More recent news

  • Autonomix picks up key nerve ablation catheter patent
  • Affluent Medical can move to pivotal phase of artificial urinary sphincter study
  • Globus Medical announces $500M share repurchase program
  • Cook Medical warns of issue with angiographic catheter
  • Virtuoso Surgical reports first cases with robotic endoscopy system, plans FDA IDE submission

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy